<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03606694</url>
  </required_header>
  <id_info>
    <org_study_id>DHM-Metformin-T2DM</org_study_id>
    <nct_id>NCT03606694</nct_id>
  </id_info>
  <brief_title>Effect of Dihydromirycetin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes Mellitus</brief_title>
  <official_title>Effect of Dihydromirycetin Administration on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Guadalajara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Guadalajara</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dihydromyricetin has demonstrated promising effects in glycemic control, insulin sensitivity
      and insulin secretion, that above mentioned findings show that dihydromyricetin has an
      excellent potential effect in the treatment of type 2 diabetes mellitus patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind, randomized clinical trial of three pharmacological groups in 36 patients with
      a diagnosis of type 2 diabetes mellitus in accordance with the American Diabetes Association
      (ADA) without treatment.

      They will be assigned randomly two groups of 12 patients, each one will receive
      dihydromyricetin 300 mg or metformin 850 mg, two times per day before having break-fast and
      before having dinner during 12 weeks.

      The Area Under the Curve of glucose and insulin will be calculated, total insulin secretion
      (Insulinogenic index), first-phase of insulin secretion (Stumvoll index) and insulin
      sensitivity (Matsuda index).

      This protocol is already approved by the local ethics committee and written informed consent
      it's going to be obtained from all volunteers.

      Statistical analysis will be presented through measures of central tendency and dispersion,
      average and deviation standard for quantitative variables; frequencies and percentages for
      variable qualitative. Qualitative variables will be analyzed by X2, will be used for
      differences inter-group Mann-Whitney U Test and Wilcoxon Test for the within-groups
      differences. It will be considered statistical significance p ≤0.05.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting glucose</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Changes in fasting glucose levels after 12 weeks of intervention with dihydromyricetin and metformin. The fasting glucose levels will be evaluated at baseline and week 12 with enzymatic/colorimetric techniques and the entered values reflect the fasting glucose level at week 12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postprandial glucose</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Changes in postprandial glucose levels after 12 weeks of intervention with dihydromyricetin and metformin. Postprandial glucose will be evaluated at baseline and week 12 after a oral glucose tolerance test with enzymatic/colorimetric techniques and the entered values reflect the insulin sensitivity at week 12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glycosylated hemoglobin</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Changes in glycosylated hemoglobin (A1C) after 12 weeks of intervention with dihydromyricetin and metformin. Glycosylated hemoglobin will be evaluated at baseline and week 12 by high pressure liquid chromatography (HPLC) and the entered values reflect the glycosylated hemoglobin at week 12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Insulin sensitivity will be calculated at baseline and week 12 with Matsuda index and the entered values reflect the insulin sensitivity at week 12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total insulin secretion</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Total insulin secretion will be calculated at baseline and week 12 with insulinogenic index and the entered values reflect the total insulin secretion at week 12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>First phase of insulin secretion</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The first phase of insulin secretion will be calculated at baseline and week 12 with Stumvoll index and the entered values reflect the first phase of insulin secretion at week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Waist Circumference</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Waist circumference will be evaluated at baseline and at week 12 with a flexible tape.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weigh</measure>
    <time_frame>Baseline, week 4, week 8 and week 12</time_frame>
    <description>The body weight will be measured at baseline, week 4, week 8 and week 12 with a bioimpedance balance and the entered values reflect the body weight at week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>Baseline, week 4, week 8 and week 12</time_frame>
    <description>Body Mas Index will be calculated at baseline, week 4, week 8 and week 12 with the Quetelet index formula and the entered values reflect the body mass index at week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C reactive protein</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>C reactive protein will be evaluated at baseline and week 12 by enzyme-linked immunosorbent assay (ELISA) and the entered values reflect the creatinine levels at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 6</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Interleukin 6 will be evaluated at the beginning and during week 12 using the enzyme-linked immunosorbent assay (ELISA) and the values entered reflect creatinine levels at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Total cholesterol levels will be evaluated at baseline and week 12 by enzymatic/colorimetric techniques and the entered values reflect the total cholesterol level at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides levels</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Triglycerides levels will be evaluated at baseline and week 12 with enzymatic/colorimetric techniques and the entered values reflect the triglycerides level at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Density Lipoprotein (c-HDL) levels</measure>
    <time_frame>Basline to Week 12</time_frame>
    <description>c-HDL levels will be evaluated at baseline and week 12 with enzymatic/colorimetric techniques and the entered values reflect the c-HDL level at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Density Lipoproteins (c-LDL) levels</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>c-LDL levels will be evaluated at baseline and week 12 with enzymatic/colorimetric techniques and the entered values reflect the c-LDL level at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine levels</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Creatinine levels will be evaluated at baseline and week 12 with enzymatic/colorimetric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine aminotransferase (ALT) levels</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>ALT levels will be evaluated at baseline and week 12 with enzymatic/colorimetric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate aminotransferase (AST) levels</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>AST levels will be evaluated at baseline and week 12 with enzymatic/colorimetric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Blood pressure will be measured at baseline and week 12 with a digital sphygmomanometer and the entered values reflect the blood pressure at week 12</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Dihydromyricetin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dihydromyricetin capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dihydromyricetin</intervention_name>
    <description>The intervention wiil be 300 mg, two times per day before break-fast and dinner during 12 weeks.</description>
    <arm_group_label>Dihydromyricetin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>The intervention wiil be 850 mg, two times per day before break-fast and dinner during 12 weeks.</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients both sexes

          -  Age between 30 and 60 years

          -  Diabetes mellitus type 2 of recent diagnosis without pharmacological treatment, with
             one of the following criteria (fasting blood glucose levels &gt;126 mg/dL; postprandial
             blood glucose levels after an oral glucose tolerance test with 75 of oral glucose &gt;200
             mg/dl; or glycosylated hemoglobin between &gt;6.5%)

          -  Informed consent signed

        Exclusion Criteria:

          -  Women with confirmed or suspected pregnancy, or under lactation and/or puerperium

          -  Previous treatment for glucose

          -  Fasting glucose ≥250 mg/dL

          -  Body Mass Index ≥34.9 kg/m2

          -  Known uncontrolled renal, hepatic, heart or thyroid diseased

          -  Hypersensibility to ingredients of intervention

          -  Triglycerides ≥500 mg/dL

          -  Total cholesterol ≥240 mg/dL

          -  Blood Pressure ≥140/90 mmHg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MANUEL GONZALEZ ORTIZ, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MANUEL GONZALEZ ORTIZ, PhD</last_name>
    <phone>+523310585200</phone>
    <phone_ext>34212</phone_ext>
    <email>uiec@prodigy.net.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>KARINA PEREZ RUBIO, PhD</last_name>
    <phone>+523310585200</phone>
    <phone_ext>34212</phone_ext>
    <email>karina2410@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MANUEL GONZAEZ, PhD</last_name>
      <phone>+523310585200</phone>
      <phone_ext>34212</phone_ext>
      <email>uiec@prodigy.net.mx</email>
    </contact>
    <contact_backup>
      <last_name>KARINA PEREZ RUBIO, PhD</last_name>
      <phone>+523310585200</phone>
      <phone_ext>34212</phone_ext>
      <email>karina2410@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Chen S, Zhao X, Wan J, Ran L, Qin Y, Wang X, Gao Y, Shu F, Zhang Y, Liu P, Zhang Q, Zhu J, Mi M. Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: A randomized controlled trial. Pharmacol Res. 2015 Sep;99:74-81. doi: 10.1016/j.phrs.2015.05.009. Epub 2015 May 30.</citation>
    <PMID>26032587</PMID>
  </reference>
  <reference>
    <citation>Wan W, Jiang B, Sun L, Xu L, Xiao P. Metabolomics reveals that vine tea (Ampelopsis grossedentata) prevents high-fat-diet-induced metabolism disorder by improving glucose homeostasis in rats. PLoS One. 2017 Aug 16;12(8):e0182830. doi: 10.1371/journal.pone.0182830. eCollection 2017.</citation>
    <PMID>28813453</PMID>
  </reference>
  <reference>
    <citation>Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet. 2011 Jul 9;378(9786):169-81. doi: 10.1016/S0140-6736(11)60614-4. Epub 2011 Jun 24. Review.</citation>
    <PMID>21705072</PMID>
  </reference>
  <reference>
    <citation>Liu L, Zhou M, Lang H, Zhou Y, Mi M. Dihydromyricetin enhances glucose uptake by inhibition of MEK/ERK pathway and consequent down-regulation of phosphorylation of PPARγ in 3T3-L1 cells. J Cell Mol Med. 2018 Feb;22(2):1247-1256. doi: 10.1111/jcmm.13403. Epub 2017 Nov 21.</citation>
    <PMID>29160030</PMID>
  </reference>
  <reference>
    <citation>Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009 Apr;58(4):773-95. doi: 10.2337/db09-9028.</citation>
    <PMID>19336687</PMID>
  </reference>
  <reference>
    <citation>Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1987 Jan;64(1):106-10.</citation>
    <PMID>3536980</PMID>
  </reference>
  <reference>
    <citation>Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005 Dec;54(12):3427-34.</citation>
    <PMID>16306358</PMID>
  </reference>
  <reference>
    <citation>van Dam RM, Naidoo N, Landberg R. Dietary flavonoids and the development of type 2 diabetes and cardiovascular diseases: review of recent findings. Curr Opin Lipidol. 2013 Feb;24(1):25-33. doi: 10.1097/MOL.0b013e32835bcdff. Review.</citation>
    <PMID>23254472</PMID>
  </reference>
  <reference>
    <citation>Wedick NM, Pan A, Cassidy A, Rimm EB, Sampson L, Rosner B, Willett W, Hu FB, Sun Q, van Dam RM. Dietary flavonoid intakes and risk of type 2 diabetes in US men and women. Am J Clin Nutr. 2012 Apr;95(4):925-33. doi: 10.3945/ajcn.111.028894. Epub 2012 Feb 22.</citation>
    <PMID>22357723</PMID>
  </reference>
  <reference>
    <citation>Le L, Jiang B, Wan W, Zhai W, Xu L, Hu K, Xiao P. Metabolomics reveals the protective of Dihydromyricetin on glucose homeostasis by enhancing insulin sensitivity. Sci Rep. 2016 Oct 31;6:36184. doi: 10.1038/srep36184.</citation>
    <PMID>27796348</PMID>
  </reference>
  <reference>
    <citation>Li H, Li Q, Liu Z, Yang K, Chen Z, Cheng Q, Wu L. The Versatile Effects of Dihydromyricetin in Health. Evid Based Complement Alternat Med. 2017;2017:1053617. doi: 10.1155/2017/1053617. Epub 2017 Aug 30. Review.</citation>
    <PMID>28947908</PMID>
  </reference>
  <reference>
    <citation>Liu L, Yin X, Wang X, Li X. Determination of dihydromyricetin in rat plasma by LC-MS/MS and its application to a pharmacokinetic study. Pharm Biol. 2017 Dec;55(1):657-662.</citation>
    <PMID>27951743</PMID>
  </reference>
  <reference>
    <citation>Xiang D, Wang CG, Wang WQ, Shi CY, Xiong W, Wang MD, Fang JG. Gastrointestinal stability of dihydromyricetin, myricetin, and myricitrin: an in vitro investigation. Int J Food Sci Nutr. 2017 Sep;68(6):704-711. doi: 10.1080/09637486.2016.1276518. Epub 2017 Jan 23.</citation>
    <PMID>28114854</PMID>
  </reference>
  <reference>
    <citation>Fan L, Tong Q, Dong W, Yang G, Hou X, Xiong W, Shi C, Fang J, Wang W. Tissue Distribution, Excretion, and Metabolic Profile of Dihydromyricetin, a Flavonoid from Vine Tea (Ampelopsis grossedentata) after Oral Administration in Rats. J Agric Food Chem. 2017 Jun 14;65(23):4597-4604. doi: 10.1021/acs.jafc.7b01155. Epub 2017 May 31.</citation>
    <PMID>28534405</PMID>
  </reference>
  <reference>
    <citation>Zhou Q, Chen K, Liu P, Gao Y, Zou D, Deng H, Huang Y, Zhang Q, Zhu J, Mi M. Dihydromyricetin stimulates irisin secretion partially via the PGC-1α pathway. Mol Cell Endocrinol. 2015 Sep 5;412:349-57. doi: 10.1016/j.mce.2015.05.036. Epub 2015 Jun 6.</citation>
    <PMID>26054747</PMID>
  </reference>
  <reference>
    <citation>Zhou Y, Wu Y, Qin Y, Liu L, Wan J, Zou L, Zhang Q, Zhu J, Mi M. Ampelopsin Improves Insulin Resistance by Activating PPARγ and Subsequently Up-Regulating FGF21-AMPK Signaling Pathway. PLoS One. 2016 Jul 8;11(7):e0159191. doi: 10.1371/journal.pone.0159191. eCollection 2016.</citation>
    <PMID>27391974</PMID>
  </reference>
  <reference>
    <citation>Wu B, Lin J, Luo J, Han D, Fan M, Guo T, Tao L, Yuan M, Yi F. Dihydromyricetin Protects against Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetic Mice. Biomed Res Int. 2017;2017:3764370. doi: 10.1155/2017/3764370. Epub 2017 Mar 21.</citation>
    <PMID>28421194</PMID>
  </reference>
  <reference>
    <citation>Liu L, Wan J, Lang H, Si M, Zhu J, Zhou Y, Mi M. Dihydromyricetin delays the onset of hyperglycemia and ameliorates insulin resistance without excessive weight gain in Zucker diabetic fatty rats. Mol Cell Endocrinol. 2017 Jan 5;439:105-115. doi: 10.1016/j.mce.2016.10.028. Epub 2016 Oct 27.</citation>
    <PMID>27984083</PMID>
  </reference>
  <reference>
    <citation>Liu TT, Zeng Y, Tang K, Chen X, Zhang W, Xu XL. Dihydromyricetin ameliorates atherosclerosis in LDL receptor deficient mice. Atherosclerosis. 2017 Jul;262:39-50. doi: 10.1016/j.atherosclerosis.2017.05.003. Epub 2017 May 5.</citation>
    <PMID>28500865</PMID>
  </reference>
  <reference>
    <citation>Shi L, Zhang T, Liang X, Hu Q, Huang J, Zhou Y, Chen M, Zhang Q, Zhu J, Mi M. Dihydromyricetin improves skeletal muscle insulin resistance by inducing autophagy via the AMPK signaling pathway. Mol Cell Endocrinol. 2015 Jul 5;409:92-102. doi: 10.1016/j.mce.2015.03.009. Epub 2015 Mar 20.</citation>
    <PMID>25797177</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 20, 2018</study_first_submitted>
  <study_first_submitted_qc>July 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Guadalajara</investigator_affiliation>
    <investigator_full_name>Manuel González Ortiz</investigator_full_name>
    <investigator_title>Researcher Professor</investigator_title>
  </responsible_party>
  <keyword>dihydromyricetin</keyword>
  <keyword>metformin</keyword>
  <keyword>type 2 diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

